Loading...
Loading...
GHRS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 13.2M |
| Operating I/L | -13.2M |
| Other Income/Expense | 2.8M |
| Interest Income | 1.5M |
| Pretax | -10.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -10.4M |
GH Research PLC is a clinical-stage biopharmaceutical company specializing in the development of therapies for psychiatric and neurological disorders. The company's primary focus is on the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of treatment-resistant depression (TRD). Their lead program, GH001, is an inhalable 5-MeO-DMT product candidate that has completed Phase 1 and Phase 1/2 clinical trials in TRD patients. Additionally, the company is developing GH002, an injectable 5-MeO-DMT product candidate, and GH003, an intranasal 5-MeO-DMT product candidate, both in preclinical development trials for psychiatric and neurological disorders.
